Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average rating of “Buy” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $117.8182.

Several research firms have weighed in on DNTH. Wells Fargo & Company began coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $63.00 to $123.00 in a research note on Tuesday, March 10th. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. Finally, Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th.

Dianthus Therapeutics Trading Up 1.0%

NASDAQ:DNTH opened at $86.16 on Monday. Dianthus Therapeutics has a 1-year low of $16.64 and a 1-year high of $96.50. The business’s 50-day moving average price is $84.70 and its two-hundred day moving average price is $58.33. The firm has a market capitalization of $4.71 billion, a price-to-earnings ratio of -20.86 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 323,021 shares of company stock worth $26,564,008. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. State Street Corp raised its position in shares of Dianthus Therapeutics by 124.7% during the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Braidwell LP acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $32,859,000. Finally, Polar Capital Holdings Plc acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $29,434,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.